Affiliations 

  • 1 Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA. chad.mire@usda.gov
  • 2 Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA
  • 3 Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA
Methods Mol Biol, 2023;2682:159-173.
PMID: 37610581 DOI: 10.1007/978-1-0716-3283-3_12

Abstract

Hendra and Nipah viruses are henipaviruses that have caused lethal human disease in Australia and Malaysia, Bangladesh, India, and the Philippines, respectively. These viruses are considered Category C pathogens by the US Centers for Disease Control. Nipah virus was recently placed on the World Health Organization Research and Development Blueprint Roadmaps for vaccine and therapeutic development. Given the infrequent and unpredictable nature of henipavirus outbreaks licensure of vaccines and therapeutics will likely require an animal model to demonstrate protective efficacy against henipavirus disease. Studies have shown that nonhuman primates are the most accurate model of human henipavirus disease and would be an important component of any application for licensure of a vaccine or antiviral drug under the US FDA Animal Rule. Nonhuman primate model selection and dosing are discussed regarding vaccine and therapeutic studies against henipaviruses.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.